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Abstract
Background. Improved survival for patients with brain metastases has been accompanied by a rise in tumor recurrence after stereotactic radiotherapy (SRT). Laser interstitial thermal therapy (LITT) has emerged as an effective
treatment for SRT failures as an alternative to open resection or repeat SRT. We aimed to evaluate the efficacy of
LITT followed by SRT (LITT+SRT) in recurrent brain metastases.
Methods. A multicenter, retrospective study was performed of patients who underwent treatment for biopsyproven brain metastasis recurrence after SRT at an academic medical center. Patients were stratified by “planned
LITT+SRT” versus “LITT alone” versus “repeat SRT alone.” Index lesion progression was determined by modified
Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.
Results. Fifty-five patients met inclusion criteria, with a median follow-up of 7.3 months (range: 1.0–30.5), age of
60 years (range: 37–86), Karnofsky Performance Status (KPS) of 80 (range: 60–100), and pre-LITT/biopsy contrastenhancing volume of 5.7 cc (range: 0.7–19.4). Thirty-eight percent of patients underwent LITT+SRT, 45% LITT alone,
and 16% SRT alone. Median time to index lesion progression (29.8, 7.5, and 3.7 months [P = .022]) was significantly
improved with LITT+SRT. When controlling for age in a multivariate analysis, patients treated with LITT+SRT remained significantly less likely to have index lesion progression (P = .004).
Conclusions. These data suggest that LITT+SRT is superior to LITT or repeat SRT alone for treatment of biopsyproven brain metastasis recurrence after SRT failure. Prospective trials are warranted to validate the efficacy of
using combination LITT+SRT for treatment of recurrent brain metastases.

Key Points
• LITT is a validated therapeutic option for metastatic brain tumor recurrence after prior SRT.
• LITT+SRT improves freedom from local progression for SRT-failed brain metastases.

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Importance of the Study

Brain metastases currently affect 10%–20% of solid tumor
cancer patients and comprise more than 50% of all intracranial tumors in adults.1 Management of recurrent brain metastasis is now a substantial and growing neuro-oncologic
challenge, with cases expected to rise as systemic therapy
for extracranial disease extends survival.2 Yet, there remains
a lack of data to guide treatment strategies in patients with
recurrent brain metastasis previously managed with stereotactic radiotherapy (SRT). The integration of modern
targeted therapy using SRT and laser interstitial thermal
therapy (LITT) presents a potential solution to achieve durable local control in this growing patient population.
Standard of care for newly diagnosed brain metastases is
dictated by tumor location and symptomatology, and typically includes a combination of radiotherapy ± surgery.2,3
Though brain metastases are historically considered
chemotherapy-resistant, blood–brain barrier-permeable
constructs, targeted therapies, and immunotherapies have
yielded promising early results as clinical trials are ongoing.2 Whole brain radiotherapy (WBRT) was previously
the standard of care for patients with multiple brain metastases. However, WBRT has increasingly been replaced
by SRT due to its associated neurocognitive toxicity.4 By
delivering ablative single or multifraction doses of radiation in a conformal manner to the target lesion or resection
bed, SRT enables durable local control rates with reduced
neurocognitive toxicity.5–8 While initially restricted to patients with limited brain metastases, accumulating evidence from randomized trials and technologic advances
such as single-isocenter multitarget treatment have broadened the indications for SRT to patients with multiple brain
metastases.9,10 However, despite these efforts, brain metastasis remains a morbid and fatal disease, with median
survival less than 12 months. Additionally, recurrence at
sites previously treated with SRT occurs in 14%–31% of patients.7,9–11 The effective management of recurrent disease,
using repeat irradiation, craniotomy, or LITT, is an active
area of investigation.12–17
LITT was initially developed for the treatment of
deep-seated tumors, utilizing a laser catheter stereotactically
placed under magnetic resonance imaging (MRI) guidance.
Once within the lesion, the activated laser thermally ablates
the tissue as MR thermometry is followed to monitor the

cohort. With strict inclusion of only biopsyproven recurrences across all treatment
groups, this study uniquely and significantly
demonstrates improved freedom from local
progression in patients treated with the combination of LITT+SRT. This finding represents
a novel and meaningful contribution to the literature on recurrent brain metastases. Future
prospective work validating the efficacy of
LITT+SRT would offer a promising development for a patient cohort with currently limited treatment options.
temperature change in real-time.18–22 Since its early clinical
translation, intracranial applications of LITT have expanded
to include both metastatic and primary brain tumors, radiation necrosis (RN), and epilepsy.12,23–27 Along with its direct
cytotoxic effect, the approach offers a minimally invasive
alternative for patients who are otherwise not candidates
for larger surgical approaches, and is associated with short
hospital stays and low patient morbidity.12,13,18,26–29 Thus far,
studies of LITT for metastatic tumor recurrence after SRT
demonstrate positive results with equivalent local control
and overall survival (OS) compared to craniotomy.13,30–32
Given these findings, we aimed to investigate whether integrating LITT with SRT improves outcomes for patients
with recurrent metastatic tumors previously treated with
radiation. We hypothesized that combined modality therapy
would improve local control compared to using LITT or SRT
alone in patients with recurrent brain tumors.

Materials and Methods
General Study and Patient Information
After IRB approval, a multi-institutional, retrospective cohort review was performed on patients who underwent
LITT+SRT, LITT alone, and repeat SRT alone between 2012
and 2019 for biopsy-proven brain metastasis recurrence
after failure of prior SRT treatment at the site of the target
lesion. Inclusion of patients from multiple institutions was
performed both for the purposes of increasing the overall
cohort counts as well as reducing selection bias given the
variation in management schemes at the different centers. The treatment decision process was multifactorial in
each patient case with consideration of LITT availability,
patient operative candidacy regarding burden of intracranial disease and functional status, and patient preferences. All LITT patients were biopsied at the time of LITT
and this study represents the subset of patients with active
tumor recurrence, while those with RN were still treated
with LITT but not included herein. Post-LITT SRT as either
single-fraction radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) was administered per institution
practice, typically between 3 and 6 weeks after ablation.
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The following study reports clinical outcomes
of biopsy-proven recurrent brain metastases
treated with repeat stereotactic radiotherapy
(SRT), laser interstitial thermal therapy (LITT),
or the combination of LITT+SRT. Prior literature investigating the efficacy of LITT+SRT
has been limited to a single case series.
Studies of repeat SRT alone have largely depended on less reliable imaging techniques
for identification of recurrent tumor versus
radiation necrosis, which limits their generalizability given potential heterogeneity in the
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Clinical and radiographic data were analyzed for disease progression or treatment response via a modified
Response Assessment in Neuro-Oncology (RANO) criteria. Failure of initial SRT treatment was determined by
the treating physician, and diagnosis of tumor recurrence
was determined by biopsy for inclusion in the study. After
subsequent treatment, local progression was defined as
significant radiographic growth >20% of the target contrastenhanced lesion volume with associated worsening symptomatology that necessitated an escalation in therapy
(bevacizumab and/or craniotomy). Sequential 1- × 1-mm
volumetric MRIs were obtained before and after treatment
and imported into the BrainLab iPlan Cranial 3.0 software
for quantitative, semi-automated volumetric analysis of
contrast-enhanced lesion volume. Subsequent local progression was not definitively identified as recurrent tumor
or RN in all events and was therefore classified as undifferentiated radiographic progression.

Statistical Analysis
GraphPad Prism version 9 was used for all statistical analyses (GraphPad Software). Categorical and continuous
data are described as frequency (percentage) and median
(interquartile range [IQR]), respectively. Fisher’s exact test
and the Mann–Whitney U or Kruskall–Wallis tests were
used for the univariate analysis of categorical and continuous data, respectively. Kaplan–Meier method was used to
generate clinical outcomes analysis. Multivariate logistic
regression analysis was performed in a stepwise manner
beginning with all variables of P <.2 on univariate analysis
iterated to only those of significance to determine the potential independent impact of treatment modality on outcomes, among other variables. A P <.05 was considered
statistically significant.

Results

Lesion Radiographic and LITT/SRT Treatment
Characteristics
The baseline radiographic characteristics of the cohorts
are shown in Table 1, with representative imaging in
Figures 1 and 2. There were no differences in lesion location or laterality between groups. There was also no statistically significant differences observed in the pre-LITT/
biopsy contrast-enhancing volume, though SRT alone
trended larger with median volumes of 5.9 cm3 (IQR 2.5–
8.1), 4.9 cm3 (IQR 3.3–19.4), and 9.3 cm3 (IQR 3.4–11.5),
respectively.
In terms of the treatment characteristics for the SRTtreated cohorts, there was no significant difference between the proportion of patients treated with FSRT or
median prescription dose between the LITT+SRT or SRTalone cohorts (83% vs. 56% fractionated and 25 [IQR 20–30]
vs. 25 [IQR 18–26] Gy prescription dose, respectively).
For the LITT-treated cohorts, there was no significant difference between the number of trajectories taken, percent coverage to yellow (reversible heat damage) thermal
damage threshold (TDT) line, or percent coverage to blue
(irreversible heat damage) TDT line between the LITT alone
and LITT+SRT groups (1 vs. 1 trajectory, 98.9% vs. 99.2%
for the yellow TDT, and 96.0% vs. 94.3% for the blue TDT, respectively). There was also no significant difference in the
hospital length of stay (median for LITT alone was 2 days
[IQR 1–3] vs. LITT+SRT 1 days [IQR 1–3]).

Clinical Outcomes by Treatment Cohort
Clinical outcomes for separate treatment cohorts are
shown in Table 1. LITT+SRT was associated with lower
rates of radiographic local progression (24% compared
to 40% for LITT alone and 67% for SRT alone). LITT+SRT
was also associated with improved median FFLP at
29.8 months compared to 7.5 and 3.7 months, respectively,
with nonprogressed patients censored at last follow-up
or death (Figure 2, P = .02). In the Kaplan–Meier survival
analysis shown in Supplementary Figure 1, LITT+SRT was
also associated with improved median OS at 12.7 months
compared to 5.9 and 6.2 months for LITT and SRS alone,
respectively (P = .03).

Cohort Demographics

Factors Associated With Tumor Progression

Retrospective chart review was performed and identified a
total of 55 patients who underwent subsequent treatment

On univariate analysis, factors that were significantly associated with decreased likelihood of tumor progression were
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of biopsy-proven, locally recurrent brain metastasis after
initial SRT treatment. Twenty-five patients underwent LITT
alone, 21 patients underwent LITT plus adjuvant SRT, and 9
patients underwent repeat SRT alone (Table 1). There were
no significant differences in age at treatment, baseline KPS,
or primary tumor histology. Groups were similar in their
systemic disease status though the LITT cohort trended to
more advancement. There was no significant difference in
prior chemotherapy or surgery. Prior WBRT was observed
more frequently among patients previously treated with
SRT alone (P = .01) while prior surgery was more common
in the LITT-alone cohort (P = .05).

Neuro-Oncology
Advances

Baseline demographic information including sex, age at
treatment, primary tumor subtype, Karnofsky Performance
Status (KPS), and prior treatment of the target lesion were
collected for all patients and compared between cohorts.
Radiographic and treatment information including target
lesion location, maximum tumor diameter/volume, pretreatment target lesion diameter/volume, and initial/adjuvant SRT dosing parameters was also collected and
compared. Our primary outcome was freedom from local
progression (FFLP) of the index lesion, defined as the time
from treatment to radiographic progression of the treated
lesion and symptom development necessitating a change
in management, with censorship when nonprogressed at
last follow-up or death.
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Table 1. Patient Baseline, Lesion, Treatment (LITT/SRT), and Posttreatment Characteristics
Variable
Age at treatment, y (IQR)
Baseline KPS, n (IQR)

56 (47.5–63.5)
7 (28%)
80 (70–90)

LITT+SRT
(n = 21, 38%)
60 (57.5–69)
14 (67%)
90 (80–100)

SRT Alone
(n = 9, 16%)

P-Value

60 (49.5–66)

NS

2 (22%)
80 (70–85)

Primary pathology, n (%)
NSCLC

.01
NS
NS

15 (60%)

6 (29%)

3 (33%)

Breast

5 (20%)

4 (19%)

5 (56%)

Melanoma

1 (4%)

3 (14%)

0 (0%)

Colon

1 (4%)

3 (14%)

0 (0%)

Other (renal, esophageal, SCLC)

3 (12%)

5 (24%)

1 (11%)

Previous surgery

5 (20%)

0 (0%)

1 (11%)

.05
.01

7 (28%)

0 (0%)

5 (56%)

Previous chemotherapy

Previous WBRT

20 (80%)

15 (71%)

4 (44%)

NS

Laterality (left), n (%)

18 (72%)

15 (75%)

4 (44%)

NS

Frontal

15 (60%)

5 (25%)

3 (33%)

Parietal

5 (20%)

8 (58%)

1 (11%)

Occipital

1 (4%)

1 (8%)

1 (11%)

Temporal

0 (0%)

1 (0%)

0 (0%)

Deep

2 (8%)

4 (0%)

1 (11%)

Cerebellar

2 (8%)

2 (8%)

Target lesion location, n (%)

Pre-LITT/biopsy contrast-enhancing volume

NS

5.9 (2.5–8.1)

4.9 (3.3–19.4)

3 (33%)
9.3 (3.4–11.5)

NS

LITT characteristics
Number of trajectories, n (range)

1 (1–2)

1 (1–1)

Coverage yellow TDT, % (IQR)

98.9% (96.8–100.0)

99.2% (93.0–100.0)

Coverage blue TDT, % (IQR)

96.0% (87.8–99.7)

94.3% (81.3–100.0)

Hospital length of stay (d), n (IQR)

2 (1–3)

1 (1–3)

—

NS

—

NS

—

NS

—

NS

SRT characteristics
Fractionated SRT, n (%)

—

19 (83%)

SRT total dose, Gray (IQR)

—

25 (25–25)

5 (56%)

NS

25 (18–26)

NS

6.2 (5.7–11.3)

.01

Posttreatment characteristics
Follow-up, mo (IQR)

5.9 (3.2–9.7)

Radiographic progression, n (%)

10 (40%)

Median time, mo

7.5

12.7 (6.8–23.4)
5 (24%)
29.8

6 (67%)
3.7

.02

Abbreviations: IQR, interquartile range; KPS, Karnofsky Performance Status; LITT, laser interstitial thermal therapy; NS, nonsignificant; NSCLC,
non-small cell lung cancer; SCLC, small cell lung carcinoma; SRT, stereotactic radiotherapy; TDT, thermal damage threshold; WBRT, whole brain
radiotherapy.
P <.05 considered significant and bolded.

  
receiving LITT+SRT, age, and prior surgery. Primary tumor
histology (non-small cell lung cancer [NSCLC] vs. others)
and pre-LITT/biopsy contrast-enhancing tumor volume
did not predict lesion progression (Table 2). Based on the
univariate analysis, the following variables met inclusion
criteria for the multivariate analysis: treatment modality,
age, prior surgery, KPS, and prior WBRT. In a stepwise regression model, the following variables were found to be
independent predictors of radiographic progression in our
cohorts: treatment modality and age. Patients treated with

LITT followed by adjuvant SRT were 5.5 times less likely
to have progression of their index lesion, when controlling
for age (Table 2, P = .004).

Discussion
To our knowledge, this is the first multi-institutional study
to investigate the relative efficacy of combining LITT with
SRT for patients with recurrent brain metastases following
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Male, n (%)

LITT Alone
(n = 25, 45%)
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1–3 months post-operative

4–6 months post-operative

LITT–
Responsive
after treatment

2.2 cm3

2.2 cm3

1.2 cm3

LITT–
Progressed
after treatment

5.1 cm3

2.6 cm3

3.3 cm3

Figure 1. Representative imaging evolution of LITT-treated lesions. The upper images were obtained from T1 post-contrast MRI sequences.
The lower images depict volumetric models of the mapped lesions. LITT, laser interstitial thermal therapy.
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Table 2. Univariate Analysis of Predictors of Tumor Progression
Variable

Hazard Ratio
(95% CI)

P-Value

Received LITT vs. repeat SRT

0.51 (0.12–1.60)

.30

Received LITT+SRT vs. others

0.45 (0.21–0.92)

.03

Age

0.94 (0.91–0.98)

.001

Sex, male

0.79 (0.39–1.62)

.52

Baseline KPS

0.97 (0.95–1.00)

.10

1.02 (0.50–2.04)

.94

WBRT

2.02 (0.79–4.52)

.11

Surgery

5.33 (1.41–16.93)

.007

1.04 (0.95–1.12)

.36

0.95 (0.91–1.0)

.04

0.18 (0.05–0.53)

.004

Univariate analysis

Prior treatment

Pre-LITT/biopsy contrastenhancing volume (cc)
Multivariate analysis
Age
 Treatment modality
(LITT+SRT)

P
Figure 2. Representative radiation isodose lines for planning postLITT stereotactic radiotherapy, corresponding to the first case in
Figure 1. Obtained from CT scan, the most central line denotes 1890
cGy radiation and the most superficial 540 cGy. LITT, laser interstitial
thermal therapy.
  

SRT failure. In this unique cohort of patients with all biopsyproven recurrent tumor, outcomes were compared to patients treated with LITT alone or SRT alone. We observed
that combining LITT with SRT significantly improves time
to index lesion progression, represented by FFLP, after a
median follow-up of 7.3 months.
The synergistic effect of combining SRT with LITT is hypothesized to stem from various biologic mechanisms. Prior
studies suggest that hyperthermia (HT) may enhance the efficacy of tumor-directed treatment through: (1) its cytotoxic/
cytoreductive effect on tumor, independent of oxygenation
or cell-cycle status; (2) enhancement of radiosensitivity via
re-oxygenation, DNA damage, and inhibition of both lethal and sublethal damage repair; (3) improvement in drug
delivery, uptake, and sensitivity; and (4) activation of host
antitumor immune responses.33–38 Several phase III trials
report improved local control by combining HT with radiation in patients with melanoma, breast, head and neck,
and esophageal cancer.7,12,13,39,40 Additionally, studies suggest that HT does not increase the incidence or severity
of normal tissue complications from radiation. However,
adoption of HT has historically been limited due to the invasive nature of thermometry and challenges for accurate
delineation and calculation of thermal doses. MRI-guided
LITT now offers a minimally invasive solution to leverage
the antitumor effects of HT and its potential synergy with
radiation to improve patient outcomes.

Abbreviations: KPS, Karnofsky Performance Status; LITT, laser
interstitial thermal therapy; NSCLC, non-small cell lung cancer; SRT,
stereotactic radiotherapy; WBRT, whole brain radiotherapy.
P <.05 considered significant and bolded.

  
The use of MRI-guided LITT in conjunction with postoperative SRT for patients with recurrent tumor after SRT
failure is an active area of investigation. The case series of
20 patients treated with LITT and SRT reported by Peña
Pino et al. demonstrated 100% local control rates at 6 and
12 months.41 While SRT is a widespread first-line treatment for the management of single and multiple brain
metastases, recurrent tumor and RN occur in 5%–15% of
SRT-treated brain lesions.42,43 As OS continues to improve
with the advent of more effective systemic therapies, the
management of recurrent disease presents a growing
neuro-oncologic challenge. LITT is currently indicated for
the treatment of primary and metastatic brain tumors, as
well as RN and epilepsy.12,18,29 The ability to reliably obtain an accurate pathological diagnosis via concomitant
biopsy and deliver effective ablative therapy represents a
technological advance. Specifically, improvements in MRIguided thermometry and the availability of intraoperative
MRI now enable surgeons to accurately monitor heat delivery to target tissues and to stereotactically position the
laser fiber within the tumor bed. LITT has an excellent
safety profile, with multiple studies reporting short hospitalizations and low complications rates.26,27,29,31 Work by
Hong et al. additionally suggests that LITT is an effective
treatment modality for the management of either recurrent tumor or RN following SRT failure. In a cohort of 75
patients, they observed equivalent progression-free survival (PFS), neurologic symptoms, and ability to taper off
steroids when compared to craniotomy.30 Our study is the
first investigation that directly compares the efficacy of
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Grabowski et al. LITT+SRT for recurrent brain metastases

LITT + SRS
LITT
SRS

FFLP

p = 0.022

50

0
0

10

30

20

40

50

Months

LITT Alone

LITT Plus SRS

# Subjects

25

21

9

# Censored subjects

15

16

3

# Events

10

5

6

7.5 Months

29.8 Months

3.7 Months

Median FFLP

Repeat SRS Alone

Figure 3. Kaplan–Meier analysis for FFLP by treatment cohort. FFLP, freedom from local progression; LITT, laser interstitial thermal therapy; SRS,
single-fraction radiosurgery.
  

combined modality treatment to LITT or SRT alone in the
recurrent setting.
The multi-institutional nature of this study, strict inclusion criteria regarding biopsy-proven recurrence, and the
use of a single guiding principle for treatment decisions
strengthen confidence in these results. Local progression
was determined using both RANO-BM criteria and a change
in symptomatology necessitating further treatment. In this
study, the median FFLP for patients treated with LITT plus
SRT was 29.8 months. This compares favorably to the LITTalone cohort, in which prior WBRT was more common,
and for which the median FFLP was 7.5 months. These outcomes agree with findings from Hong et al. and Rao et al.,
who reported a 6-month PFS of 75.6% and 75.8%, respectively, with LITT alone after SRT failure.30,31 The difference
in prior WBRT between the cohorts is largely a function of
the SRT-alone cohort being treated at earlier timepoints
when WBRT was a more widely used treatment modality.

This could also reflect differences in prognostic category,
though that is less likely to influence subsequent local
progression than it would OS measures. Although the difference was not statistically significant, there was higher
percentage of fractionation in the LITT+SRT group (83%
in LITT+SRT group, 56% in SRT group), which may have
been a result of expected lesion expansion post-LITT. A hypothesized rationale for a combinatorial approach emerges
in which LITT treats both recurrent tumor and any component of RN within the lesion, and the addition of FSRT
eliminates any tumor at the periphery that was left viable
despite LITT.
Approximately 50% of tumor histologies were either
NSCLC or melanoma, and the impact of targeted therapy
and immunotherapy on overall outcomes on this patient
population is well documented. Further characterization of
tumor heterogeneity and molecular classifications would
be beneficial given the demonstrated impact on outcomes;
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performance status or deep-seated lesions for whom surgical intervention could compromise neurologic function.
Future prospective studies are needed to validate these results and to determine whether LITT+SRT improves FFLP
and other clinical outcome measures.

Supplementary Material
Supplementary material is available at Neuro-Oncology
Advances online.
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